Related Experiment Video

Updated: Oct 24, 2025

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.0K

Impact of Adiponectin Resistance on Coronary Artery Disease Severity

S Stojanovic1, M D Ilic1, S Ilic1

  • 1Clinic for Cardiovascular Diseases, Institute for Prevention, Treatment and Rehabilitation "Niska Banja", Nis, Serbia.

Nigerian Journal of Clinical Practice
|August 16, 2021
PubMed

Insights

Low serum adiponectin levels and high Homeostasis Model Assessment-Adiponectin (HOMA-AD) index are associated with coronary artery disease (CAD) and metabolic syndrome (MetS). These markers may help identify patients at risk for CAD.

Area of Science:

  • Cardiology
  • Metabolic Syndrome Research
  • Biomarker Discovery

Background:

  • Serum adiponectin (AD) and adiponectin resistance (AD-R) may indicate metabolic syndrome (MetS) severity.
  • The prognostic role of AD-R and Homeostasis Model Assessment-Adiponectin (HOMA-AD) in coronary artery disease (CAD) severity requires further understanding.

Purpose of the Study:

  • To determine adiponectin concentration and HOMA-AD index in patients with CAD, with or without MetS.
  • To evaluate the prognostic importance of AD and HOMA-AD on CAD severity.

Main Methods:

  • Cross-sectional study of 130 participants divided into CAD+MetS, CAD-MetS, and control groups.
  • Biochemical, anthropometric, and coronary angiography data were analyzed.
  • Serum adiponectin measured by ELISA; Gensini score, Duke prognostic index, and HOMA-AD calculated.

Main Results:

  • Serum adiponectin levels were significantly lower in CAD+MetS and CAD-MetS groups compared to controls.
  • HOMA-AD index positively correlated with MetS parameters and CAD severity indicators (Gensini score, number of lesions).
  • Adiponectin, blood pressure, HOMA-IR, and HOMA-AD were significant predictors of CAD; specific cut-off values identified higher risk.

Conclusions:

  • Patients with CAD, with or without MetS, exhibit low adiponectin levels.
  • Hypoadiponectinemia and elevated HOMA-AD index may serve as valuable markers for identifying patients at risk for CAD.
Abstract

Keywords:
AdiponectinDuke prognostic indexGenssini scorecoronary angiographycoronary artery diseaseinsulin resistance

More Related Videos

Author Spotlight: The Significance of Isolation, Culture, and Adipogenic Induction of SVF-Derived Preadipocytes from Mouse Perivascular Adipose Tissue06:56

Author Spotlight: The Significance of Isolation, Culture, and Adipogenic Induction of SVF-Derived Preadipocytes from Mouse Perivascular Adipose Tissue

Published on: July 21, 2023

2.5K
Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

3.2K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
523
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
101
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
85
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
413
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
75
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
593